Biocon has announced that it has received marketing authorisation from the Drugs Controller General of India (DCGI) for its novel biologic ‘Itolizumab’ – anti-CD6 molecule, for the treatment of chronic plaque Psoriasis.
Itolizumab with a mechanism of action (MOA) and safety profile as indicated during the 52-week Phase-III multi-centric clinical study conducted in India. It is the second novel biologic developed by Biocon. Kiran Mazumdar-Shaw, Chairman & Managing Director, Biocon in a release said,
“The marketing authorisation for Itolizumab from DCGI will enable Biocon to introduce this novel, first in class biologic for the treatment of psoriasis patients in India. This is our second novel biologic that we have developed in India, BioMab EGFR, an anti-cancer monoclonal antibody, being the first.”